Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Beyond chip: Ccrs predicts prolonged cytopenias and inferior survival following anti-BCMA CAR-T in multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

DSDavid Scheiber-CamorettiEMElliot MerrittRGRebecca Gonzalez

Discussion

Loading...

Member takes

Overview

Analysis of patients receiving anti-BCMA CAR-T therapy shows CCRS correlates with prolonged cytopenias and survival outcomes.

Key Points

  • Ccrs significantly predicts prolonged cytopenias and worse survival outcomes in multiple myeloma patients.
  • In patients treated with anti-BCMA CAR-T therapy, those with high CCRS experienced notably lower survival rates.
  • Observational analysis of outcomes utilized multivariable Cox regression modeling to assess survival and other key factors.
  • Findings emphasize the need for integrating Ccrs-based monitoring strategies into treatment plans for better patient care.

Cite This Study

Scheiber-Camoretti et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dca4https://doi.org/10.1182/blood-2025-930
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1The simple c-reactive protein (CRP) to albumin ratio (CAR) stratifies treatment response and survival following chimeric antigen receptor T-cell therapy for non-Hodgkin's lymphoma2025
  2. 2CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)2025
  3. 3Pre-existing clonal hematopoiesis in CAR-T recipients is not associated with increased immunotoxicity and inflammatory serum signatures2025
  4. 4Early intervention for cytokine release syndrome after chimeric antigen receptor T-cell therapy is associated with an increased risk of cytopenias and infections in patients with large B-cell lymphoma2025
  5. 5Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy2025